Powered by

Glycyx PharmaVentures and Valeant Pharmaceuticals Agree to Binding Terms of Licensing Agreement in the Field of Oncology

Mar 15, 2017 - Business Wire

Glycyx PharmaVentures Ltd. ("Glycyx"), a biopharma investment and development company founded by Lorin K. Johnson, Ph.D., has agreed to enter into an exclusive license agreement with Valeant Pharmaceuticals International, Inc. ("Valeant"), pursuant to which Valeant will grant to Glycyx a license or sublicense to develop and commercialize products containing methylnaltrexone bromide for oncology indications in countries outside the US and Canada, with the right to extend the license to the US and...